Search

Displaying results 3841 - 3850 of 7607 in total
  1. Drug

    MK-0752

    go.drugbank.com/drugs/DB12852
    Investigational

    Mk 0752 is under investigation in clinical trial NCT00572182 (MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer).

  2. Drug

    Amfecloral

    go.drugbank.com/drugs/DB08924
    Experimental

    For a short period of time, it was available under the brand Acutran and indicated as an appetite suppressant, but this product no longer exists. … It acts as a prodrug which splits to form amphetamine and chloral hydrate, similarly to clobenzorex and related compounds, except that the N-substituent, in this case, yields a compound that is active

  3. Drug

    BB-1701

    go.drugbank.com/drugs/DB17443
    Investigational

    BB-1701 is a humanized IgG1 kappa monoclonal antibody (anti-HER2 antibody) conjugated to eribulin developed by Bliss Biopharmaceutical.

    Synonyms: Humanized IgG1kappa monoclonal antibody (anti-HER2 antibody) conjugated to eribulin
  4. Drug

    P-113D

    go.drugbank.com/drugs/DB04987
    Experimental

    It is being pursued as a potential treatment for cystic fibrosis by Demegen, Inc.

  5. Drug

    OMS-103HP

    go.drugbank.com/drugs/DB05303
    Investigational

    OMS103HP is the first drug being developed to improve joint function following arthroscopic surgery, one of the most common procedures performed today by orthopedic surgeons.

  6. Drug

    XTL-001

    go.drugbank.com/drugs/DB05405
    Investigational

    XTL001 is an investigational monoclonal antibody (MAb) product developed by XTL Biopharmaceuticals to evaluate the safety profile and antiviral activity of the compound in patients chronically infected

  7. Drug

    AVX-001

    go.drugbank.com/drugs/DB19194
    Investigational

    Subjects With AK). … AVX-001 is under investigation in clinical trial NCT05164393 (Phase I/iia Trial to Evaluate AVX001 Gel in Doses of 1% or 3% Compared With Vehicle Over Four Weeks of Field-directed Treatment Period in Adult

  8. Drug

    Elacridar

    go.drugbank.com/drugs/DB04881
    Investigational

    In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacridar was not listed on GSK's product pipeline. … Development is assumed to have been discontinued.

  9. Drug

    AT-7519

    go.drugbank.com/drugs/DB08142
    Investigational

    AT7519 is a selective inhibitor of certain Cyclin Dependent Kinases (CDKs) leading to tumour regression. It is developed by Astex for the treatment of solid tumours and haematological malignancies.

    Synonyms: 4-{[(2,6-dichlorophenyl)carbonyl]amino}-N-piperidin-4-yl-1H-pyrazole-3-carboxamide
  10. Drug

    Oxaprotiline

    go.drugbank.com/drugs/DB09307
    Experimental

    Both enantiomers have antidepressant effects but levoprotiline also is an antihistamine and dextroprotiline has many other pharmacological actions. … Oxaprotiline is a norepinephrine reuptake inhibitor of the tetracyclic antidepressant family that is related to maprotiline. This drug was never marketed.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome